Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has shared an update.
CANbridge Pharmaceuticals Inc. announced that its enzyme replacement therapy, CAN 103, has been included in China’s first ‘Commercial Health Insurance Innovative Drug List,’ effective January 1, 2026. This inclusion marks a significant milestone for the company, as it ensures broader treatment coverage for Gaucher disease patients and enhances medication accessibility. The move is part of the company’s strategy to deepen its domestic R&D and commercialization efforts, supported by China’s healthcare security system.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the development, production, and commercialization of innovative therapies, particularly for rare diseases. The company is committed to enhancing the accessibility of high-quality treatment options for patients in China.
Average Trading Volume: 2,904,016
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.21B
Find detailed analytics on 1228 stock on TipRanks’ Stock Analysis page.